Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel

Reuters

2025/07/08

Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> in Israel

Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046466) on July 08, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549547479"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549547479\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549547479?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549547479","market":"nz","top_or_hot":-1,"title":"Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a> in Israel\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XBIO\">Xenetic Biosciences Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046466) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-08 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a> in Israel\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XBIO\">Xenetic Biosciences Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046466) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL69MZ4X:1","article_id":"2549547479","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549547479","pubTimestamp":1751979633,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps  in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XBIO":"Xenetic Biosciences Inc"},"translate_title":"Xenetic Biosciences宣布在以色列启动DNase I治疗胰腺癌的探索性临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBIO":0.9},"content_text":"Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel\n    \n\n        Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046466) on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}